Skip to main content

Press releases | February 22, 2021

Fried Frank advised Catalent, Inc. in connection with the issuance of $550 million aggregate principal amount of 3.125% senior notes due 2029. The net proceeds were used to (i) redeem in full its 4.875% senior notes due 2026, plus any accrued and unpaid interest thereon, (ii) pay related fees and expenses, and (iii) provide cash on its balance sheet for general corporate purposes, including capital expenditures.

Catalent, Inc. is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products.

The Fried Frank team was led by corporate partners Daniel J. Bursky and Joshua Thomas Coleman.


This communication is for general information only. It is not intended, nor should it be relied upon, as legal advice. In some jurisdictions, this may be considered attorney advertising. Please refer to the firm’s data policy page for further information.